NCT07677098

Brief Summary

To compare postprandial plasma amino acid availability, expressed as incremental area under the curve (iAUC), over a 6 hour period following ingestion of 25 g of different protein isolates in healthy, young adults. The primary objective is divided into the following 2 sub-studies, each with 3 comparisons:

  • Sub-study 1: whey protein, calcium caseinate, sodium caseinate.
  • Sub-study 2: calcium caseinate, magnesium caseinate, potassium caseinate.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
10mo left

Started Sep 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 24, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 30, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

September 15, 2026

Expected
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2027

Last Updated

June 30, 2026

Status Verified

June 1, 2026

Enrollment Period

10 months

First QC Date

June 24, 2026

Last Update Submit

June 24, 2026

Conditions

Keywords

Amino acidSatiety hormoneMineralsProtein kinetics

Outcome Measures

Primary Outcomes (1)

  • Six-hour postprandial plasma total amino acid availability following ingestion of 25 grams of different protein isolates in healthy, young adults

    Plasma total amino acid availability is expressed as the incremental area under the curve (iAUC) and compared between whey protein, calcium caseinate and sodium caseinate (sub-study 1) and between calcium caseinate, magnesium caseinate and potassium caseinate (sub-study 2).

    Six hours

Secondary Outcomes (5)

  • Plasma essential amino acid concentrations

    Essential amino acid concentrations are derived from blood samples taken before beverage ingestion and during the six-hour postprandial time-period (at 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300 and 360 minutes following beverage ingestion).

  • Non-essential amino acid concentrations

    Nonssential amino acid concentrations are derived from blood samples taken before beverage ingestion and during the six-hour postprandial time-period (at 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 300 and 360 minutes following beverage ingestion).

  • Plasma amino acid kinetics

    During the six-hour postprandial period

  • Circulating mineral concentrations

    During the six-hour postprandial period

  • Glucagon-like peptide-1 concentrations

    During the six-hour postprandial period

Study Arms (5)

Whey protein

ACTIVE COMPARATOR

25 g whey protein isolate

Dietary Supplement: Protein beverage

Sodium caseinate

EXPERIMENTAL

25 g sodium caseinate protein

Dietary Supplement: Protein beverage

Calcium caseinate

EXPERIMENTAL

25 g calcium caseinate protein

Dietary Supplement: Protein beverage

Magnesium caseinate

EXPERIMENTAL

25 g magnesium caseinate protein

Dietary Supplement: Protein beverage

Potassium caseinate

EXPERIMENTAL

25 g potassium caseinate protein

Dietary Supplement: Protein beverage

Interventions

Protein beverageDIETARY_SUPPLEMENT

25 g protein isolate, dissolved in 500 mL water

Calcium caseinateMagnesium caseinatePotassium caseinateSodium caseinateWhey protein

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
To be eligible to participate in this study, a participant must meet all of the following criteria: * Male or female sex * Aged between 18 - 35 years inclusive * BMI between 18 - 30 kg/m2 * Healthy, recreationally active (exercise at least once per two weeks and a maximum of four days per week) * No physical limitations (i.e., able to perform all activities associated with daily living independently) A potential participant who meets any of the following criteria will be excluded from participation in this study: * Intolerant to milk protein and/or dairy-based products * Smoking regularly * Diagnosed with gastro-intestinal disorders * Diagnosed with metabolic disorders (e.g. diabetes) * Diagnosed with musculoskeletal disorders * Blood donation in the past 2 months * Females: pregnancy * Use of any medication known to affect protein metabolism (e.g. corticosteroids, non-steroidal anti-inflammatories or prescribed acne medications) * Chronic use of gastric acid suppressing drugs (e.g. proton pump inhibitors, H2-antagonists)

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Maastricht University Medical Centre

Maastricht, Limburg, 6200, Netherlands

Location

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
The protein drinks will be prepared by a member of the study team, not involved in the data collection. Subjects receive protein beverages in a non-transparent shaker.
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Within-subject, randomized, double-blind, cross-over design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2026

First Posted

June 30, 2026

Study Start (Estimated)

September 15, 2026

Primary Completion (Estimated)

July 15, 2027

Study Completion (Estimated)

July 15, 2027

Last Updated

June 30, 2026

Record last verified: 2026-06

Locations